InnoCan Pharma Corporation (INNPF)
OTC PINK OTC PINK Primary Summary
INNPF Chart
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Herzliya, Israel and Calgary, Alberta, October 21, 2024 – PRISM MediaWire – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental
InnoCan Pharma Corporation (INNPF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has InnoCan Pharma Corporation ever had a stock split?
InnoCan Pharma Corporation Profile
| Diversified Consumer Services Industry | Consumer Discretionary Sector | Iris Bincovich CEO | OTC PINK Exchange | 45783P102 CUSIP |
| CA Country | 11 Employees | - Last Dividend | 5 Sep 2025 Last Split | - IPO Date |
Overview
InnoCan Pharma Corporation is a pioneering pharmaceutical technology company with a keen focus on developing innovative drug delivery platforms that merge cannabidiol (CBD) with other pharmaceutical ingredients. The company's operations span across the United States, Canada, Europe, and other international markets. It is structured into two main segments: Pharmaceuticals and Consumer Wellness. At its core, InnoCan Pharma is committed to advancing the research and development of CBD loaded exosomes and the LPT CBD-loaded liposome platform. These platforms are designed to ensure precise dosing and the sustained, controlled release of CBD into the bloodstream, targeting conditions such as epilepsy and pain management. Established in 2018 and based in Calgary, Canada, InnoCan Pharma is at the forefront of integrating CBD into pharmaceutical and topical treatment products, aiming to bridge the gap between the health benefits of CBD and the needs of patients worldwide.
Products and Services
- CBD loaded exosomes - This innovative research and development project focuses on utilizing exosomes (cell-derived nanoparticles) as a delivery system for cannabidiol (CBD). The aim is to target specific diseases with precision, enhancing the therapeutic effects of CBD.
- LPT CBD-loaded liposome platform - A sophisticated drug delivery platform that encapsulates CBD in liposomes. This technology facilitates accurate dosing and ensures a prolonged and controlled release of CBD into the bloodstream. It is primarily developed for use in managing conditions like epilepsy and chronic pain.
- Branded CBD integrated pharmaceutical and topical treatment products - InnoCan Pharma is actively involved in the commercialization and sale of branded pharmaceutical and topical treatments that integrate CBD. These products are designed to meet the needs of patients seeking reliable, CBD-based therapies.
- Self-care products for a healthier lifestyle - Beyond its pharmaceutical technology focus, InnoCan also develops and markets a range of self-care products. These offerings aim to promote a healthier lifestyle through the benefits of CBD and other wellness-focused ingredients.
- Product Brand Names - The company markets its diverse product portfolio under several brand names, including Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On. Each brand caters to different aspects of health and wellness, leveraging the therapeutic potential of CBD.
